Responses
Other responses
Jump to comment:
- Published on: 11 October 2022
- Published on: 11 October 2022
- Published on: 11 October 2022Response to Dickinson´s and McConnell´s letter - authors replyShow More
Dear Editor,
We appreciate the electronic letter from Dickinson and McConnell who refer to our review “Inhaled beta 2-agonists and performance in competitive athletes”. They make the point that maintaining the formal requirement to apply for a TUE (therapeutic use exemption) before the start of therapy with inhaled beta 2-agonists in asthmatic athletes in the long term leads to improved medical care and diagnost...
Conflict of Interest:
None declared. - Published on: 11 October 2022Abbreviated TUE's have improved service deliveryShow More
Dear Editor,
We read with great interest the recent review from Kinderman and Meyer in the recent supplement in the BJSM entitled ‘Inhaled ß2-agonists and performance in competitive athletes’. They raise the issue as to whether it is appropriate for inhaled ß2-agonists to require an abbreviated TUE before an athlete is allowed to use them in order to attenuate their asthma/EIA. They put fo...
Conflict of Interest:
None declared.